Effect of High Levels of Oxygen and Smoking on the Lungs in Human Volunteers

Sponsor
National Heart, Lung, and Blood Institute (NHLBI) (NIH)
Overall Status
Completed
CT.gov ID
NCT00001464
Collaborator
(none)
77
1
142.6
0.5

Study Details

Study Description

Brief Summary

Patients with lung disease experiencing difficulty breathing can be treated with oxygen therapy. This involves the delivery of "extra" oxygen by a face-mask or through small tubes placed in the nose called nasal prongs. This extra oxygen can have concentrations as high as 100% pure oxygen. The concentration of oxygen in normal air is only 21%. The high concentration of oxygen can help to provide enough oxygen for all of the organs in the body. Unfortunately, breathing 100% oxygen for long periods of time can cause changes in the lungs, which are potentially harmful. Researchers believe that by lowering the concentration of oxygen therapy to 40% patients can receive it for longer periods of time without the risk of side effects.

This study is designed to evaluate the effects of oxygen therapy at 100% and 40% for 12 18 hours on the lungs of normal volunteers. Results of this study will help to determine if levels of oxygen therapy currently accepted as being "safe" may actually be damaging to the lungs.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Stress such as high oxygen or inflammation can result in damage to proteins by processes such as oxidation or alternative regulation of signaling pathways by post-translational modification of proteins (e.g., phosphorylation). Delivery of oxygen in high concentrations to the lungs can result in damage, which is mediated in large part by reactive oxygen species. Inflammation can result in activation of intracellular signaling pathways. This study will evaluate modification of proteins and nucleic acids in bronchoalveolar lavage fluid, bronchial epithelial cells, and peripheral blood of individuals exposed to oxygen or who are smokers. In doing so, it will determine the effects of hyperoxia or inflammation on the lung.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    77 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Prospective
    Official Title:
    Effect of Hypoxia and Smoking on Oxidation of Proteins and Nucleic Acids in Human Volunteers
    Actual Study Start Date :
    Aug 22, 1995
    Actual Primary Completion Date :
    Jul 10, 2007
    Actual Study Completion Date :
    Jul 10, 2007

    Arms and Interventions

    Arm Intervention/Treatment
    Group 1

    Smokers exposed to oxygen

    Outcome Measures

    Primary Outcome Measures

    1. To determine whether hyperoxia of relatively limited duration (up to l8 hrs) is associated with oxidation of proteins and nucleic acids in lung cells. [1 week]

      To determine whether hyperoxia of relatively limited duration (up to l8 hrs) is associated with oxidation of proteins and nucleic acids in lung cells.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    • INCLUSION CRITERIA:

    History - good overall health without history of recent (within 3 months) acute disease;

    Physical examination within normal limits;

    Laboratory evaluation; including complete blood count (CBC), serum electrolyte determinations, clotting times, chest x-ray, pulmonary function testing, and an electrocardiogram (EKG) - within normal limits;

    Non-smokers defined as having never smoked or not smoked in the past 2 years;

    Smokers defined as moderate (1 pack per day for 3+ years) or heavy (1-2 packs for 10+ years);

    Subjects must be willing to make the time commitment necessary for the study.

    EXCLUSION CRITERIA:

    Any study subject who does not fulfill the criteria for eligibility.

    Individuals with a history of allergy or adverse reactions to atropine or any local anesthetic;

    Individuals testing positive for the human immunodeficiency virus or hepatitis virus;

    Individuals on chronic medications or currently receiving medications;

    Pregnant or lactating individuals, since the effects of hyperoxia on the fetus are unclear.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda Maryland United States 20892

    Sponsors and Collaborators

    • National Heart, Lung, and Blood Institute (NHLBI)

    Investigators

    • Principal Investigator: Joel Moss, M.D., National Heart, Lung, and Blood Institute (NHLBI)

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    National Heart, Lung, and Blood Institute (NHLBI)
    ClinicalTrials.gov Identifier:
    NCT00001464
    Other Study ID Numbers:
    • 950167
    • 95-H-0167
    First Posted:
    Nov 4, 1999
    Last Update Posted:
    Aug 27, 2021
    Last Verified:
    Aug 1, 2021
    Keywords provided by National Heart, Lung, and Blood Institute (NHLBI)

    Study Results

    No Results Posted as of Aug 27, 2021